on POXEL (EPA:POXEL)
Poxel's Recovery Plan and December Shareholders Meeting
Poxel SA, a biopharmaceutical firm, has announced it is finalizing its recovery plan. Key goals include the ongoing development of Imeglimin, PXL770, and PXL065, securing new financing, and resolving existing debts. The initiatives are supported by IPF Partners.
Shareholders are invited to a meeting on December 11, 2025, to discuss the 2024 financial statements and capital-related delegations. Proposed financial measures include a capital increase with preferential subscription rights and a debt offsetting exercise reserved for IPF Partners.
Without shareholder approval, Poxel may face judicial liquidation proceedings. Presently, no takeover offers or alternative financing solutions have been proposed.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all POXEL news